Business Context and Reporting Period
Company: Nano Dimension Ltd. (NNDM)
Filing Type: Form 8-K (Current Report)
Date of Report: June 15, 2026
Event: Execution of a non-binding term sheet for a proposed business combination with Infinite Epigenetics, Inc. ("Infinite").
Key Financial Metrics and Transaction Terms
This filing details a proposed transaction structure rather than historical financial performance. Key valuation and financial terms include:
- Infinite Valuation: $890 million, less a defined "Premium."
- Nano Valuation Basis: Calculated as 100% of Nano's actual Net Cash at closing, plus a 20% premium on that amount, plus an agreed valuation for Essemtec (estimated at $20 million) and other remaining assets.
- Consideration: Infinite equity holders will receive Nano ordinary shares (or ADSs) based on the exchange ratio derived from the valuations above.
- Legacy Assets: Nano shareholders retain rights to benefit from post-closing dispositions of legacy assets, businesses, technology, and IP not included in the Net Cash calculation.
- Break-up Fee: Nano may reimburse Infinite up to $3 million for legal and accounting expenses if a definitive agreement is not executed by the next Extraordinary General Meeting (EGM) date, subject to specific conditions.
Material Changes and Governance
The filing outlines significant changes to corporate governance and strategic direction contingent on the transaction's completion:
- Board Composition: The post-transaction board will consist of seven members. Infinite will designate four members. If Infinite shareholders own greater than 55% of the combined company on a fully diluted basis, Infinite's designation rights increase to five members.
- Ownership Structure: Nano shareholders are expected to retain a meaningful minority ownership interest post-transaction.
- Exclusivity: A binding 30-day exclusivity period prohibits both parties from soliciting or negotiating other acquisition proposals, though Nano retains the ability to dispose of Legacy Assets.
Guidance, Outlook, and Risks
Outlook and Next Steps:
- The transaction is subject to the execution of a Definitive Agreement and necessary shareholder approvals.
- Nano intends to file a proxy statement for an Extraordinary General Meeting to seek non-binding advisory approval regarding the strategic alternatives review process.
- A registration statement on Form S-4 (Proxy Statement/Prospectus) is expected to be filed upon execution of the Definitive Agreement.
- Execution Risk: Failure to negotiate a definitive agreement or satisfy closing conditions.
- Regulatory Risk: Delays or failure to obtain required governmental or regulatory approvals.
- Market Risk: Fluctuations in Nano's share price relative to the Term Sheet valuations could alter the final ownership percentages.
- Operational Risk: Potential disruption to business operations, retention of key personnel, and business relationships.
- Legacy Asset Risk: Possibility that Nano shareholders may never receive proceeds from Legacy Assets.
Investor Verification Checklist
- Verify the definition of "Net Cash" in the Term Sheet to understand the baseline for Nano's valuation.
- Confirm the timeline for the Extraordinary General Meeting (EGM) and the deadline for executing the Definitive Agreement.
- Review the upcoming Proxy Statement/Prospectus (Form S-4) for definitive terms, as this 8-K is based on a non-binding term sheet.
- Assess the status of Nano's "Legacy Assets" and the mechanism for their potential disposition to shareholders.
- Monitor Nano's cash position and the estimated $20 million valuation of Essemtec for accuracy in the final deal structure.